A Unique in vivo Approach to Producing Epitope-specific MHCII TCR-like Antibodies 9257

Abstract Description The ability to observe, detect, and track the presentation of specific epitopes via major histocompatibility complex II (MHCII) can be a valuable tool in the context of many immunological questions. The current available methods most often used, such as, mass spectrometry, T-cell recognition and ELISPOT assays are limited in their utility and functionality, while soluble T cell receptors (TCR) have proven to be difficult to engineer and often have low affinity for their target. TCR-like antibodies capable of recognizing epitope-specific MHCII with high affinity and specificity are a preferable tool in many cases. However, current methods of TCR-like antibody production are time intensive and often require the building of comprehensive antibody libraries with multiple rounds of selection to determine antibodies of high affinity for their target. Therefore, we sought to develop a reliable and efficient pipeline capable of producing epitope-specific TCR-like antibodies of high affinity without the need for in vitro affinity optimization. Here we utilize lipid nanoparticle delivery of single-chain peptide-MHCII mRNA constructs to mice and rely on the in vivo antibody maturation process and rigorous selection of high affinity clones to develop monoclonal TCR-like antibodies. Through our pipeline we can successfully produce TCR-like antibodies of high affinity and specificity, and we continue to optimize it to do so consistently and reliably. Funding Sources Supported by NIAID 1R01AI180250-01A1 Topic Categories Antigen and Dendritic Cell Processing, Presentation, and Biology (AGDC)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2025-11-01
DOI
https://doi.org/10.1093/jimmun/vkaf283.2682
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Unique in vivo Approach to Producing Epitope-specific MHCII TCR-like Antibodies 9257

Michael J. Hogan, Linlin Yang, Laurence C. Eisenlohr, Dominic Lapadula
The Journal of Immunology
CAR-T cell therapy research
article

A Unique in vivo Approach to Producing Epitope-specific MHCII TCR-like Antibodies 9257

Michael J. Hogan, Linlin Yang, Laurence C. Eisenlohr, Dominic Lapadula
article en

Abstract

Abstract Description The ability to observe, detect, and track the presentation of specific epitopes via major histocompatibility complex II (MHCII) can be a valuable tool in the context of many immunological questions. The current available methods most often used, such as, mass spectrometry, T-cell recognition and ELISPOT assays are limited in their utility and functionality, while soluble T cell receptors (TCR) have proven to be difficult to engineer and often have low affinity for their target. TCR-like antibodies capable of recognizing epitope-specific MHCII with high affinity and specificity are a preferable tool in many cases. However, current methods of TCR-like antibody production are time intensive and often require the building of comprehensive antibody libraries with multiple rounds of selection to determine antibodies of high affinity for their target. Therefore, we sought to develop a reliable and efficient pipeline capable of producing epitope-specific TCR-like antibodies of high affinity without the need for in vitro affinity optimization. Here we utilize lipid nanoparticle delivery of single-chain peptide-MHCII mRNA constructs to mice and rely on the in vivo antibody maturation process and rigorous selection of high affinity clones to develop monoclonal TCR-like antibodies. Through our pipeline we can successfully produce TCR-like antibodies of high affinity and specificity, and we continue to optimize it to do so consistently and reliably. Funding Sources Supported by NIAID 1R01AI180250-01A1 Topic Categories Antigen and Dendritic Cell Processing, Presentation, and Biology (AGDC)

The Journal of ImmunologyVol. 214(Supplement_1)
Children's Hospital of Philadelphia (US), University of Pennsylvania (US), Philadelphia University (US)
Openalex Percentile: Top 52%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A Unique in vivo Approach to Producing Epitope-specific MHCII TCR-like Antibodies 9257 — Michael J. Hogan, Linlin Yang, et al. · The Journal of Immunology (2025) | TGRS Research Map | TGRS